Dr. Eugene Seymour, M.D., MPH, is the Chief Executive Officer of NanoViricides, Inc.Dr. Seymour began practicing medicine in Los Angeles/Beverly Hills in the late 1960s. In late 1981, he began treating patients with a strange new disease affecting primarily the gay population. In 1986, he was requested by the U.S. government to establish a testing laboratory and run a large-scale surveillance program for HIV prevalence in the Hispanic population in Los Angeles. His laboratory ended up testing over 50,000 people. Because of his belief that prevention, in the absence of a cure, was critical to stem the rising tide of HIV infections, he founded a company, now called StatSure, Inc., in 1989. He raised the capital and oversaw the development of a rapid HIV antibody blood test, Hema-Strip. In 1993, as Chief Executive Officer, he took the company public as a Nasdaq company. Under his direction, the company conducted research studies in Africa, Asia, South and North America. The Hema-Strip was approved in a number of countries including Canada, Great Britain and Vietnam. Dr. Seymour left the company in 1996 to run a nonprofit foundation, which funded both testing and training programs for health workers in Asia and Africa. He became a consultant to the U.N. Global Program on AIDS, and was sent to a number of different countries — Lithuania, Latvia, Estonia and Russia — to interact with local physicians and assist them in setting up testing programs. Two years later, he became Director of Strategic Alliances at a medical education startup called medschool.com that was later acquired by a group of investors. Dr. Seymour is the holder of eight issued patents. Originally trained as a chemist, he decided to attend medical school in preparation for a career as a clinical investigator. Following postgraduate medical training, he obtained a master's degree in the epidemiology of infectious diseases at UCLA. He began clinical practice in internal medicine and joined the UCLA medical school faculty. He left UCLA after two years and joined the USC faculty as Associate Professor. He served in the Medical Corps of U.S. Army Reserve during the Vietnam era and attained the rank of major. Profile
TWST: Would you provide us with a brief summary of where the company is right now?
Dr. Seymour: As you know, we have developed a platform technology to rapidly create drugs to destroy